0001493152-26-022751
SEC filingAinos, Inc. reported Q1 2026 financial results with revenue of $161, net loss of $2.46 million, operating expenses down 30% year-over-year, and strengthened cash position to $2.84 million.
Ainos reported Q1 2026 results reflecting a transitional phase in its AI Nose commercialization strategy, with revenue dropping sharply to $161 from $106,207 in the prior year due to shifting focus from earlier revenue streams to industrial and infrastructure deployments in semiconductors and healthcare. Gross loss widened as cost of revenues exceeded minimal sales, but management highlighted ongoing execution of a $2.1 million backend semiconductor contract targeting 1400 systems, alongside new pilots in front-end fabs and hospital settings like HVAC and MRI environments. Operating expenses declined significantly by approximately 30% year-over-year to $2.28 million, driven by reductions in R&D (to $1.69 million) and SG&A (to $0.59 million), demonstrating fiscal discipline amid commercialization ramp-up. The net loss improved to $2.46 million from $3.29 million YoY, supported by lower non-operating expenses. Balance sheet strengthened notably with cash rising to $2.84 million from $0.42 million at December 31, 2025, via a NT$90 million (~$2.8 million) financing, while related-party convertible notes adjusted to $11 million total. CFO Christopher Lee noted liquidity enhancements position the company for H2 2026 revenue opportunities, with CEO Eddy Tsai emphasizing Smell ID dataset expansion and SLM refinement for scalable enterprise adoption in AI-driven environmental intelligence.